Richard Rorty thinks he has the same agenda as Donald Davidson. He is wrong. Though Rorty contends truth as only metaphor liberates us, he actually undercuts a rich interpretative ability. Davidson's agenda provides ...Richard Rorty thinks he has the same agenda as Donald Davidson. He is wrong. Though Rorty contends truth as only metaphor liberates us, he actually undercuts a rich interpretative ability. Davidson's agenda provides ways to explore this ability by elucidating the conditions that reside in the make up of successful communication and in which truth claims are made about the world. Thus, Davidson and Rorty have different agenda, and Davidson's offers more promise for philosophy to help explain what we seem to know-we can communicate truthfully about the world.展开更多
Bayer Schering Pharma,a division of Bayer Health Care,said on February 12th it will investEuro 100 million (US$129 million) in a new global research and development center inBeijingg over the next five years.China is...Bayer Schering Pharma,a division of Bayer Health Care,said on February 12th it will investEuro 100 million (US$129 million) in a new global research and development center inBeijingg over the next five years.China is the third largest market worldwide for the Bayer group,and it will become the third countrybesides Germany and the U.S.to host such a center for its Bayer Schering Pharma unit.展开更多
文摘Richard Rorty thinks he has the same agenda as Donald Davidson. He is wrong. Though Rorty contends truth as only metaphor liberates us, he actually undercuts a rich interpretative ability. Davidson's agenda provides ways to explore this ability by elucidating the conditions that reside in the make up of successful communication and in which truth claims are made about the world. Thus, Davidson and Rorty have different agenda, and Davidson's offers more promise for philosophy to help explain what we seem to know-we can communicate truthfully about the world.
文摘Bayer Schering Pharma,a division of Bayer Health Care,said on February 12th it will investEuro 100 million (US$129 million) in a new global research and development center inBeijingg over the next five years.China is the third largest market worldwide for the Bayer group,and it will become the third countrybesides Germany and the U.S.to host such a center for its Bayer Schering Pharma unit.